<DOC>
<DOCNO>
EP-0000833
</DOCNO>
<TEXT>
<DATE>
19790221
</DATE>
<IPC-CLASSIFICATIONS>
C07F-9/00 A61P-9/00 H01L-29/10 C07F-9/572 A61K-31/675 H01L-29/02 A61P-9/12 H01L-29/78 H01L-29/66 <main>C07F-9/65</main> A61K-33/42 
</IPC-CLASSIFICATIONS>
<TITLE>
derivatives of phosphonoacyl prolines and their pharmaceutical use.
</TITLE>
<APPLICANT>
squibb & sons incus  <sep>e.r. squibb & sons, inc.<sep>e.r. squibb &amp; sons, inc.lawrenceville-princeton roadprinceton, n.j. 08540-4000us<sep>e.r. squibb & sons, inc.<sep>
</APPLICANT>
<INVENTOR>
ondetti miguel a<sep>petrillo edward w<sep>ondetti, miguel a.<sep>petrillo, edward w.<sep>ondetti, miguel a.79 hemlock circleprinceton new jerseyus<sep>petrillo, edward w.433 sked streetpennington new jerseyus<sep>ondetti, miguel a.  <sep>petrillo, edward w.<sep>ondetti, miguel a.79 hemlock circleprinceton new jerseyus<sep>petrillo, edward w.433 sked streetpennington new jerseyus<sep>
</INVENTOR>
<ABSTRACT>
new phosphonoacyl prolines and related compounds  have the general formula    where r₁ and r₂ each is hydrogen, lower alkyl, lower  alkenyl, unsubstituted or substituted phenyl-lower alkyl, or a  metal ion;r₃ is hydrogen or lower alkyl;r₄ is hydrogen, lower  alkyl, phenyl-lower alkyl or a metal ion; and n is 0 or 1.  these compounds may be used as hypotensive agents in  the treatment of mammals.  
</ABSTRACT>
</TEXT>
</DOC>
